Research and Development Archives – Page 4 of 8

Story: Live Attenuated SHIV Vaccine Associated with Virus Clearance in Macaques

November 15, 2021
Dorrit Walsh

November 2021 Examples of media coverage: Research team develops vaccine that kills HIV in monkeys - The Asahi Shimbun, November 9, 2021 A New Vaccine Kills HIV in Monkeys. And It's Coming to Humans in 5 Years - Interesting Engineering,…

Update on HIV Vaccine Research

November 11, 2021
Dorrit Walsh

Developing an HIV vaccine is a difficult scientific challenge, but remains a critical priority. This handout provides an update on HIV vaccine research and a summary of results from the efficacy trials that have been conducted to date, and it…

Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

November 4, 2021
Dorrit Walsh

This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.

Delivering on the Promise of Long-Acting Technologies

October 3, 2021
Dorrit Walsh

By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers…

Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing

August 27, 2021
Dorrit Walsh

TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.

Comments to NIH Leadership Regarding the Proposed Advanced Research Projects Agency for Health

August 5, 2021
Dorrit Walsh

In response to the Biden administration's intention to create a new research agency under the NIH called the Advanced Research Projects Agency for Health (ARPA-H), TAG and AVAC were invited to present remarks and guidance on the behalf of the Federal AIDS Policy Partnership and Research Work Group (RWG).

Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries

July 27, 2021
Dorrit Walsh

The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs), home to 75% of those living with this viral illness.

TAG Testimonies on Funding Priorities FY22 to Senate LHHS and Related Agencies

July 9, 2021
Dorrit Walsh

On June 24, TAG submitted testimony to the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies outlining funding priorities for fiscal year 2022.

The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times

May 10, 2021
Dorrit Walsh

This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.

Cover of Tuberculosis Research Funding Trends 2005-2019

2020 Report on TB Research Funding Trends

December 7, 2020
Dorrit Walsh

TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.